Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beam Therapeutics Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Individuals with sickle cell trait |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biologic Specimen Collection | Other | Participants will have blood and urine collected at Baseline |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin variant quantification | Determine range of variability in baseline %HbS in SCT subjects and relationship of baseline %HbS to markers of hemolysis (LDH, reticulocytes, haptoglobin), coagulopathy (D-dimer), and renal disease (urine albumin/creatinine ratio) | Through study completion, an average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Red blood cell rheology | Identify range of variation in baseline RBC rheological parameters in SCT subjects and relationship to %HbS, other baseline clinical parameters | Through study completion, an average of 2 years |
| Natural History |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults aged 18 and older with sickle cell trait.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julie Kanter, MD | Contact | (202) 596-1548 | jkanter@sicklecellcenters.org |
| Name | Affiliation | Role |
|---|---|---|
| Julie Kanter, MD | National Alliance for Sickle Cell Centers | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama | Recruiting | Birmingham | Alabama | 35294 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
For individuals who consent to provide optional DNA testing, an alpha globin sequencing (ATHAL) test will be included.
Evaluate the frequency of hemolysis
| Through study completion, an average of 2 years |
| Loma Linda University Health Care | Recruiting | Loma Linda | California | 92354 | United States |
|
| Nemours Children's Hospital | Recruiting | Wilmington | Delaware | 19803 | United States |
|
| Indiana University | Recruiting | Indianapolis | Indiana | 46202 | United States |
|
| Functional Fluidics | Recruiting | Detroit | Michigan | 48202 | United States |
|
| University of North Carolina | Recruiting | Chapel Hill | North Carolina | 27599 | United States |
|
| Duke University | Recruiting | Durham | North Carolina | 27710 | United States |
|
| East Carolina University | Recruiting | Greenville | North Carolina | 27834 | United States |
|
| Nationwide Children's Hospital | Recruiting | Columbus | Ohio | 43205 | United States |
|
| UT Health Houston | Recruiting | Houston | Texas | 77030 | United States |
|
| ID | Term |
|---|---|
| D012805 | Sickle Cell Trait |
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided